What should I look for in a therapeutic antibody discovery partner?

A strong therapeutic antibody discovery partner should bring more than a discovery platform. Look for a team that can connect target biology, immunization strategy, functional screening, antibody characterization, developability assessment, protein production, and candidate selection into one development-aware workflow. The right partner should help you identify antibodies with the right biological function, not just binding activity.

How does MindWalk support therapeutic antibody discovery?

MindWalk supports the full continuum of therapeutic antibody discovery, from target analysis and antigen design through hit discovery, functional screening, lead characterization, humanization, optimization, and candidate selection. Each program is customized around the target biology, modality, mechanism of action, development path, and candidate diversity goals, including specialized strategies for challenging targets. With broad discovery experience, MindWalk works closely with clients as a scientific partner to help advance antibodies with the right functional and development profile.

Does MindWalk support difficult targets or novel mechanisms?

Yes. Difficult targets require workflows built around the biology, not a fixed discovery path. MindWalk works as your scientific partner, bringing 35+ years of antibody discovery and development experience to complex targets, difficult epitopes, novel mechanisms, and programs with limited biological precedent. Programs can combine wet lab discovery, AI-enabled analysis, functional selection, lead characterization, optimization, protein engineering, production, and candidate selection. MindWalk has contributed to 20+ publicly disclosed client antibodies that have advanced to the clinic. Publicly disclosed programs only.

What does function-first therapeutic antibody discovery mean?

Function-first therapeutic antibody discovery means antibody candidates are evaluated early for biological activity and program-relevant performance, not only for binding affinity. This helps teams assess whether candidates fit the intended mechanism, disease biology, assay context, and downstream therapeutic goals.

How does AI improve therapeutic antibody discovery?

Our scientists use LensAI™ analysis to compare antibody candidates across the evidence that matters, not sequence similarity or binding strength alone: biological context, structure, function, assay data, developability considerations, immunogenicity considerations, and candidate diversity. These insights support clearer candidate comparison before optimization, scale-up, or further antibody development.

Can MindWalk help optimize lead antibody candidates?

Yes. Lead optimization is where early discovery promise is tested against development reality. MindWalk can support candidate characterization, affinity optimization, developability review, immunogenicity assessment, and wet lab validation to help teams advance stronger candidates with fewer late-stage liabilities.

What antibody formats can MindWalk support?

MindWalk supports multiple therapeutic antibody formats, including full-length IgG, bispecific antibodies, VHH/nanobodies, scFv, Fab, F(ab’)2, custom formats, and fusion constructs.

Can MindWalk support VHH discovery?

Yes. MindWalk has announced B cell Llama™, a VHH single-domain camelid discovery platform designed for bispecific, multispecific, and cell therapy applications.

Function-first therapeutic antibody discovery.

Therapeutic antibodies selected for function, not just binding.

From target analysis to a humanized, optimized candidate, one team runs the program. Rabbit, chicken, camelid, and mouse repertoires. B cell Select® function-first screening. 20+ publicly disclosed client antibodies have advanced from our lab into clinical development. Publicly disclosed programs only; additional client antibodies have advanced under partner confidentiality.

Discuss your target

Built around your target.

End-to-end antibody discovery and development built around your program goals.

One team from target to candidate, no handoffs between vendors.

Developability and immunogenicity risk assessed before it costs a wet-lab cycle.

Every candidate comes with the evidence behind its ranking, from LensAI™ analysis and from the bench.

Speed

Reduced time to lead selection, risk flagged earlier.

Diversity

Rare, high-value candidates brought into focus across phenotypic diversity.

Confidence

>98% B cell Select® success*; risk considerations brought forward.

*“Success” refers to meeting predefined discovery criteria, not clinical or therapeutic outcomes. Results may vary.

Speed

Reduced time to lead selection, risk flagged earlier.

Diversity

Rare, high-value candidates brought into focus across phenotypic diversity.

Confidence

>98% B cell Select® success*; risk considerations brought forward.

*“Success” refers to meeting predefined discovery criteria, not clinical or therapeutic outcomes. Results may vary.

Your success is our success

Collaboration drives every project. We listen, adapt, and align with your goals, applying scientific and technological rigor with advanced workflows. For us, success is measured by the progress of your discoveries.

LensAI™ analysis, built into the program.

At the target: profiling, off-target and cross-reactivity, antigen design, epitope prediction, structure prediction.

At hit selection: epitope mapping, affinity prediction, developability, immunogenicity screening, hit expansion.

At the lead: humanization, de-risk engineering, affinity optimization, specificity and selectivity. Powered by HYFT® technology.

What a therapeutic program includes

Target

Target Analysis
Tool Generation
LensAI™ target analysis

Discovery

Immunization Strategies
B cell Select® Antibody Discovery
Hybridoma Antibody Discovery
Yeast Display Antibody Discovery
B cell Llama™ VHH Antibody Discovery
De novo Design
LensAI™ candidate ranking and optimization

Leads

Lead Characterization
Lead Optimization
Protein Engineering and Production
LensAI™ candidate ranking and optimization

Candidate Selection

Research Cell Bank Generation

Functional selection

Internalization
Neutralization
Epitope Mapping
Affinity, Specificity, Developability
Custom Cell-based and Plate-based Assays

Species Diversity

Rabbit + Chicken + Camelid + Mice

Immunization Strategies

Protein + Genetic + Peptide + Whole Cell

Format Options

Full-length IgG
Bispecific Antibodies (bsAbs)
VHH Single-Domain Camelid
scFv, Fab, F(ab’)2
Custom Formats
Fusion Constructs

Case Studies

See validated insights that redefine workflows and advance discovery

See case studies

Scientific Posters

Discover how MindWalk powers smarter paths from concept to clinic.

See posters

Blogs

Explore latest ideas reshaping the future of discovery.

Read the blog

Antibodies in the clinic

Therapeutic antibodies selected for function, not just binding.

Built around your target.

Speed

Diversity

Confidence

Speed

Diversity

Confidence

Your success is our success

Where our research makes a broad impact

Biologics discovery across complex targets

20+ publicly disclosed client antibodies have advanced from our lab into clinical development. Publicly disclosed programs only; additional client antibodies have advanced under partner confidentiality.

End-to-end antibody discovery + development

LensAI™ analysis, built into the program.

What a therapeutic program includes

See how B cell Select®, hybridoma, and yeast display discovery work, and where LensAI™ analysis fits. Learn more

Expanding discovery innovation

Used by teams across 19 of the top 20 pharma companies, next-gen biotechs, and top research institutions.

Tell us about your target.

A scientist, not a sales rep, replies within two business days.

Case Studies

Scientific Posters

Blogs

FAQs